Aktis Oncology vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 53)
Aktis Oncology logo

Aktis Oncology

ChallengerHealthcare & Life Sciences

Radiopharmaceuticals

Clinical-stage oncology company completed $318M IPO in Jan 2026 — first biotech IPO of 2026 (Nasdaq: AKTS); Eli Lilly took $100M stake; developing alpha-emitting radiopharmaceutical AKY-1189 targeting Nectin-4 for bladder and other solid tumors.

AI VisibilityBeta
Overall Score
C53
Category Rank
#252 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
52
Perplexity
57
Gemini
53

About

Aktis Oncology is a Boston-based clinical-stage oncology company developing alpha-emitting radiopharmaceuticals against prevalent solid tumors. The company completed a $318 million IPO in January 2026 — the first significant biotech IPO of 2026 — pricing 17.65 million shares at $18 each on the Nasdaq under ticker AKTS. Eli Lilly stepped in to purchase $100 million of the offering.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
up
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

53
Overall Score
93
#252
Category Rank
#1
78
AI Consensus
80
stable
Trend
up
52
ChatGPT
94
57
Perplexity
89
53
Gemini
94
47
Claude
92
54
Grok
98

Key Details

Category
Radiopharmaceuticals
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Aktis Oncology
Radiopharmaceuticals

Integrations

Only Aktis Oncology
Only Pfizer
Pfizer is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.